Table 2 Associations between clinicopathological characteristics and RAI-refractory DTC

Age (years)

0.089

≥ 40

30 (83.3)

30 (66.7)

2.5 (0.89–7.31)

< 40

6 (16.7)

15 (33.3)

1 (ref)

Sex

0.061

Male

13 (36.1)

8 (17.8)

2.61 (0.94–7.27)

Female

23 (63.9)

37 (82.2)

1 (ref)

Histological type

0.066

Follicular-derived carcinomas, high-grade

7 (19.4)

1 (2.2)

14.00 (0.94–207.60)

FTC

1 (2.8)

3 (6.7)

0.67 (0.039–11.29)

PTC

26 (72.2)

37 (82.2)

1.41 (0.24–8.25)

IEFVP

2 (5.6)

4 (8.9)

1 (ref)

Aggressive subtype

< 0.001*

Aggressive

14 (38.9)

2 (4.4)

13.68 (2.85–65.64)

Nonaggressive

22 (61.1)

43 (95.6)

TNM staging

< 0.001*

II-IV

19 (52.8)

1 (2.2)

48.18 (6.10–396.52)

I

17 (47.2)

44 (97.8)

1 (ref)

LVI

< 0.001*

Yes

33 (91.7)

14 (31.1)

24.36 (6.38–93.01)

No

3 (8.3)

31 (68.9)

1 (ref)

m-ETE

< 0.001*

Yes

32 (88.9)

11 (24.4)

24.73 (7.14–85.62)

No

4 (11.1)

34 (75.6)

1 (ref)

AXL expression

> 10% (high)

30 (83.3)

21 (46.7)

5.71 (1.99–16.40)

0.001*

0–10% (negative/low)

6 (16.7)

24 (53.3)

1 (ref)

TERT promoter

Mutation

21 (58.3)

2 (4.4)

30.10 (6.29–143.95)

< 0.001*

Wild-type

15 (41.7)

43 (95.6)

1 (ref)